Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…
No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current…
The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…
The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral (ARV) agents, particularly the latest single-tablet regimens (STRs), which offer improved safety and…
In late age-related macular degeneration (AMD), vision deficits are noticeable, are often debilitating, and can be a precursor to blindness. The availability of vascular endothelial growth factor (…
Ulcerative colitis (UC) affects approximately 1.75 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild and moderate patients; however,…
Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. CKD is characterized by a progressive loss of…
The maturing, but highly lucrative, market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is becoming increasingly fragmented as attractive new options enter a powerful…
Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly; DRG forecasts PD prevalence to grow 2% annually in the major pharmaceutical markets through…
Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and…
Chronic Hepatitis C (HCV) affects several thousand people in Brazil and Colombia. New therapies allow cure in a short period of time with minimal side effects, in contrast to older options. Brazil…
The term dyslipidemia refers to abnormalities in the composition, concentration, or size of lipoproteins in the circulation. Dyslipidemia is a key modifiable risk factor for cardiovascular (CV)…
The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-alpha) inhibitors and interleukin-12 and…